CoChat
Sign Up
Cited by 44BRCA gene mutations in cancerCancer Treatment and PharmacologyNanoparticle-Based Drug Delivery

nab-Paclitaxel (Abraxane®): an albumin-bound cytotoxic exploiting natural delivery mechanisms into tumors

Open access
Iglesias, J·2009·Breast Cancer Research
DOI 10.1186/bcr2282PMC PMC4284885
Open this paper in CoChat — free accountOpen PDF

Abstract

There has been progress in the identification of factors that confer important risk for the development of breast cancer.The factors include: heritable mutations in susceptibility genes; exposure to therapeutic radiation during breast development (as for Hodgkin's disease survivors who received therapeutic radiation to the chest); and histologic lesions, including LCIS and atypical hyperplasias.Testing for mutations in the BRCA1 and BRCA2 breast ovarian cancer susceptibility genes has become part of the established care of breast cancer patients.Genetic information from BRCA1/2 testing is used to help healthy at-risk women to avoid breast and/or ovarian cancer, and ultimately to avoid death from those cancers.Data accumulated over the past decade have provided evidence that breast cancer surveillance can be improved with the addition of breast MRI, that prophylactic oophorectomy substantially reduces the risk of ovarian cancer and, when performed before menopause, can reduce the risk of breast cancer as well, and that prophylactic mastectomy reduces the risk of breast cancer by more than 90%.It has been observed that approximately 80% of BRCA1-associated breast cancers are negative for ER, PR and HER2 (so-called triple negative) and cluster with basal-like breast cancers by DNA microarray, while 80% of BRCA2-associated breast cancers are ER + and PR + , but HER2 negative, and luminal.These data are surprising given the close relationships between these genes in their DNA repair activities, and raise some concern that hormonal interventions will not successfully reduce the risk of BRCA1-associated breast cancers.Other strategies may be necessary to reduce breast cancer risk for this group.Genetic information has been shown to have important implications for women with breast cancer as well.Women with strong family histories of breast and/or ovarian cancer, and women diagnosed before age 40 may consider testing at the time of breast cancer diagnosis if they would use the information to make treatment decisions.Some women choose bilateral mastectomies over breast-conserving treatment if they learn that their risk of second primary breast cancer exceeds 50%, and if their prognosis from the original breast cancer is good.Some women opt for oophorectomy as part of the management of their ER + breast cancer if they are premenopausal mutation carriers (and could participate in TEXT).Recently, novel agents, the PARP inhibitors, have been shown to be effective in the phase II trials in women with BRCA1 or BRCA2 mutations and metastatic ovarian or breast cancer.These drugs target DNA repair pathways that are particularly vulnerable in women with BRCA1/2 mutations.The agents may also be effective in women with sporadic breast cancer, and are currently in trials in Europe and the United States alone and in combination with cytotoxic agents. S2 Magnetic resonance imaging for diagnosis, staging, and follow-up M Morrow

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/bcr2282

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Successful targeting of human prostate cancer cell lines by PTX-loaded bovine serum albumin nanoparticles decorated with folic acid has been observed.

    “The successful targeting of human prostate cancer cell lines by PTX-loaded bovine serum albumin nanoparticles, which are created using a dissolving process and decorated with folic acid, has been observed.62”

    From Smart nanoparticles for cancer therapy (2023) · cites this paper as [62]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Gnant M, Mlineritsch B, Schippinger W, et al.: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
  2. Eidtmann H, Bundred N, De Boer R, et al.: The effect of zole- dronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving letrozole: 36 months follow-up of ZO-FAST [abstract 44]. Pre- sented at 31st San Antonio Breast Cancer Symposium; 10-14 December 2008;

Cited by

Sorted by citations

Related

Authors
Iglesias, J.
Affiliations
Abraxis (United States) (US)
Corresponding author
Iglesias, J
Venue
Breast Cancer Research
Publisher
Springer Science and Business Media LLC
Published
2009-06
Volume
11
Issue
S1
ISSN
  • 1465-5411 (ISSN-L)
  • 1465-542X
DOI
10.1186/bcr2282
PMC
PMC4284885
OpenAlex
W2027236774
Cited by
44
References
3
Citations by year
2026: 6 · 2025: 4 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 2 · 2019: 2 · 2018: 4 · 2017: 2 · 2015: 1 · 2014: 1 · 2012: 4
FWCI
1.94
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (unspecified)
Locations
  • Breast Cancer Research (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
Funders
AstraZeneca
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
nab-paclitaxel, breast cancer, BRCA1, BRCA2, hereditary breast and ovarian cancer, genetic testing, breast cancer risk reduction, prophylactic oophorectomy, prophylactic mastectomy, PARP inhibitors, DNA repair, triple-negative breast cancer, basal-like breast cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review